COVID-19 Vaccination Update

Cecilia W. Stuopis, MD
January 6, 2021
Medical Director and Department Head
MIT Medical
MIT Medical COVID-19 Vaccine Approach

Phase 1
December – February
• Highly constrained supply with distribution tightly controlled by Commonwealth
• Eligible Populations:
  • MIT Medical employees and contractors with patient contact and/or COVID-19 exposure risk
  • MIT Police
  • MIT EMS

Phase 2
February – April
• Increasing supplies distributed more broadly by Commonwealth
• Eligible Populations:
  • MIT Medical patients with two or more comorbidities, or who are age 75+
  • MIT Medical patients age 65+
  • MIT Medical patients with one comorbidity
  • Select MIT employees who support critical infrastructure (i.e., CUP)

Phase 3
April onward
• Widespread availability with health care providers able to order doses based on need
• Eligible Populations:
  • Broader populations TBD
Update: MIT Medical has received and administered vaccine

• First batch of Moderna vaccine (200 doses) received 12/23
  • Vaccine was administered to 168 frontline MIT Medical personnel on 12/28, 29, & 30
  • No reports of significant side effects
  • Additional vaccinations planned for 1/7 for MIT Medical personnel in the first tranche who were unable to be vaccinated last week

• Second batch of 200 Moderna vaccine doses arrived on 1/5
  • Will continue to vaccinate MIT Medical clinical personnel, and
  • MIT Police, and
  • MIT EMS

• We anticipate that we will have excess vaccine from the first two batches
  • Continue to vaccinate MIT Medical, Police, EMS personnel
  • Reaching out to the Commonwealth regarding whether we can move into Phase 2 once MIT’s Phase 1 is complete/near complete
  • At this time, excess vaccine will remain frozen and will be used for the second round of vaccines for those already immunized
Plans for Phase 2

• *The Commonwealth is clear that we are still in Phase 1*
• Phase 2 will not commence until the Commonwealth approves moving to that phase
• The MIT Medical Population Health and Medical Informatics team is generating a list of our patients who meet the criteria for Phase 2a:
  • Individuals with 2+ [co-morbid conditions](#) and/or age 75+ (high risk for COVID-19 complications)
### CDC Co-morbidities

<table>
<thead>
<tr>
<th>Underlying medical conditions that <strong>have increased risk</strong> of severe illness from COVID-19 (clearly Phase 2 eligible)</th>
<th>Underlying medical conditions that <strong>might</strong> have increased risk of severe illness from COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Cancer <em>(current)</em></td>
<td>• Asthma <em>(moderate-to-severe)</em></td>
</tr>
<tr>
<td>• Chronic kidney disease</td>
<td>• Cerebrovascular disease <em>(affects blood vessels and blood supply to the brain)</em></td>
</tr>
<tr>
<td>• COPD <em>(chronic obstructive pulmonary disease)</em></td>
<td>• Cystic fibrosis</td>
</tr>
<tr>
<td>• Down Syndrome</td>
<td>• Hypertension or high blood pressure</td>
</tr>
<tr>
<td>• Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies</td>
<td>• Immunocompromised state <em>(weakened immune system)</em> from solid organ transplant, immune deficiencies, HIV, use of corticosteroids, or use of other immune weakening medicines</td>
</tr>
<tr>
<td>• Immunocompromised state <em>(weakened immune system)</em> from solid organ transplant</td>
<td>• Neurologic conditions, such as dementia</td>
</tr>
<tr>
<td>• Obesity <em>(body mass index [BMI] of 30 kg/m² or higher but &lt; 40 kg/m²)</em></td>
<td>• Liver disease</td>
</tr>
<tr>
<td>• Severe Obesity <em>(BMI ≥ 40 kg/m²)</em></td>
<td>• Overweight <em>(BMI &gt; 25 kg/m², but &lt; 30 kg/m²)</em></td>
</tr>
<tr>
<td>• Pregnancy</td>
<td>• Pulmonary fibrosis <em>(having damaged or scarred lung tissues)</em></td>
</tr>
<tr>
<td>• Sickle cell disease</td>
<td>• Thalassemia <em>(a type of blood disorder)</em></td>
</tr>
<tr>
<td>• Smoking</td>
<td>• Type 1 diabetes mellitus</td>
</tr>
<tr>
<td>• Type 2 diabetes mellitus</td>
<td>• Type 2 diabetes mellitus</td>
</tr>
</tbody>
</table>
Plans for Phase 2 (continued)

• When we are allowed to proceed with Phase 2, MIT Medical will directly contact eligible patients to offer appointments for immunization

• Phase 2 immunizations for patients will most likely be given at MIT Medical
  • Documented in our electronic medical record
  • Patients must be observed for 15 minutes after administration

• We are asking that patients of MIT Medical kindly refrain from calling or messaging providers and staff at MIT Medical to inquire about when they will be vaccinated. We are already seeing significant volumes of these inquiries, and they delay our responses to other clinically important questions

• Please trust that we will reach out if you are eligible

• We are actively investigating the possibility of being a Commonwealth-approved employer-based vaccination site so that we can vaccinate other members of the MIT community